Ignite Creation Date:
2024-05-06 @ 9:22 AM
Last Modification Date:
2024-10-26 @ 12:13 PM
Study NCT ID:
NCT02965560
Status:
COMPLETED
Last Update Posted:
2018-06-06
First Post:
2016-11-14
Brief Title:
Exploring Biomarkers Predicting the Outcome of Acute-on-chronic Liver Failure
Sponsor:
First Affiliated Hospital of Zhejiang University
Organization:
First Affiliated Hospital of Zhejiang University
Study Overview
Official Title:
A Study on Biomarkers Predicting the Outcome of Acute-on-chronic Liver Failure
Status:
COMPLETED
Status Verified Date:
2016-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
PGE2
Brief Summary:
Acute-on-chronic liver failure ACLF is an ailment with high incidence of multiorgan failure MOF and consequent mortality Systemic inflammation and susceptibility to infection are characteristic pathophysiological features Prostaglandin E2 PGE2 could subdue systemic inflammation and alleviate liver injury in mice model However there are no studies evaluating PGE2 as a predictor of early mortalityThis study is designed to investigate whether plasma PGE2 and its receptors are associated with development of MOF and predict short-term mortality in patients with acute-on-chronic liver failure By the way we will also measure several other potential predictive factors C-reactive proteinsevere hyponatremia Second infectionsDiabetes mellitusHigh density lipoproteininterleukin-10serum bile acidsferritinthe neutrophil to lymphocyte ratiosoluable urokinase plasminogen activator receptorvWF-Ag levels and FVIII-to-PC ratios
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None